Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both The TRAPEZE Randomized Clinical Trial
Nicholas D James, Sarah J Pirrie, Ann M Pope, Darren Barton, Lazaros Andronis, Ilias Goranitis, Stuart Collins, Adam Daunton, Duncan McLaren, Joe O'Sullivan, Christopher Parker, Emilio Porfiri, John Staffurth, Andrew Stanley, James Wylie, Sharon Beesley, Alison Birtle, Janet Brown, Prabir Chakraborti, Syed Hussain Show all
JAMA Oncology | AMER MEDICAL ASSOC | Published : 2016
Awarded by UK National Institute for Health Research Health Technology Assessment Programme (NIHR HTA)
Awarded by Public Health Agency
Sanofi Aventis and Novartis Pharmaceuticals supported the trial with educational grants and support for drug costs or trial discount for sites, respectively, and GE Healthcare also offered a trial discount to sites purchasing strontium-89. The TRAPEZE trial was an independent research project commissioned and funded by the UK National Institute for Health Research Health Technology Assessment Programme (NIHR HTA No. 06/303/205). The NIHR HTA will publish the full trial results in the Health Technology Assessment journal later in 2015; the NIHR HTA encourages publication of trial results journals but was not involved in the decision to do so here.